Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Blinded, Single-Dose, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

NCT02780674 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02780674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02780674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Blinded, Single-Dose, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
August 26, 2016
Completion date
November 27, 2017
Enrollment
36 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, polymyositis, sjogren's, sle, ssc